Table 2.
Synergistic activity of GRFT and CG against SARS-CoV-1 and SARS-CoV-2 PsVs.
| Compounds | EC50 ¶ (µg/mL) | ||||
|---|---|---|---|---|---|
| SARS-CoV-1 | SARS-CoV-2 Wuhan | SARS-CoV-2 D614G | SARS-CoV-2 K1417N/E484K/N501Y | ||
| GRFT | 12.5 | 20.6 | 37.6 | 31.6 | |
| ι-CG | 4.3 | 7.5 | 6.5 | 6.7 | |
| λ-CG | 4.2 | 6.1 | 4.5 | 3.2 | |
| ι-CG + GRFT 1:3 ratio | 3.8 | 2.5 | 2.7 | 1.7 | |
| λ-CG + GRFT 1:3 ratio | 0.7 | 3.2 | 2.8 | 1.9 | |
| ι-CG + GRFT 1:5 ratio | 0.2 | 0.7 | 0.5 | 0.4 | |
| λ-CG + GRFT 1:5 ratio | 0.4 | 0.4 | 0.6 | 0.3 | |
| Combination | CI values * | ||||
| SARS-CoV-1 | SARS-CoV-2 Wuhan | SARS-CoV-2 D614G | SARS-CoV-2 K1417N/E484K/N501Y | ||
| ι-CG + GRFT | ED50 | ND | ND | 0.19910 | 0.28442 |
| ED75 | ND | ND | 0.11192 | 0.19067 | |
| ED90 | ND | ND | 0.07208 | 0.13426 | |
| λ-CG + GRFT | ED50 | 0.61385 | 0.66908 | 0.35799 | 0.62309 |
| ED75 | 0.30337 | 0.51784 | 0.25653 | 0.43368 | |
| ED90 | 0.18899 | 0.40843 | 0.19111 | 0.30924 | |
¶ EC50: half-maximal effective concentration; * combination index (CI): a quantitative measure of the degree of drug interaction in terms of additive effect (CI = 1), synergism (CI < 1), or antagonism (CI > 1) is shown for a given end point of the effect measurement; ND: not determined.